Cell-free fetal DNA

EchelonDx and Cradle Genomics Join Forces to Accelerate Development of Comprehensive Non-Invasive Prenatal Diagnostic Products

Retrieved on: 
Monday, May 3, 2021

b"Echelon Diagnostics, Inc. , a leading provider of genomic healthcare AI imaging analysis and big data solutions, and Cradle Genomics, Inc. , inventors of a novel prenatal testing methodology, today announced an agreement that will help accelerate the development of Cradle\xe2\x80\x99s innovative cellular-based non-invasive prenatal diagnosic (NIPD) products.

Key Points: 
  • b"Echelon Diagnostics, Inc. , a leading provider of genomic healthcare AI imaging analysis and big data solutions, and Cradle Genomics, Inc. , inventors of a novel prenatal testing methodology, today announced an agreement that will help accelerate the development of Cradle\xe2\x80\x99s innovative cellular-based non-invasive prenatal diagnosic (NIPD) products.
  • Cradle Genomics' proprietary assay technology was designed to overcome this challenge by isolating and utilizing intact cells, which increases the purity of fetal DNA and enables diagnostic testing as early as the fifth week of pregnancy.
  • Cradle is developing novel fetal genetic analysis and pregnancy health solutions at the earliest stages of pregnancy.
  • Based in Reno, Nevada, the company continues to advance the field of genomics by supporting its growing number of customers around the world.

Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies

Retrieved on: 
Tuesday, December 1, 2020

"We believe we are on track to achieve profitability in our Women's Health business in 2021."

Key Points: 
  • "We believe we are on track to achieve profitability in our Women's Health business in 2021."
  • The test uses a unique single-nucleotide polymorphism (SNP)-based technology to analyze fetal/placental DNA obtained through a blood draw from the mother.
  • It is the only commercially available test that differentiates between maternal and fetal DNA to assess the risk of aneuploidies.
  • The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health.

NIPT for Average Risk Now Covered for 139 Million Commercial Lives

Retrieved on: 
Thursday, October 29, 2020

This is the latest in a string of medical policy changes in 2020 that have more than doubled the number of covered lives for average risk NIPT.

Key Points: 
  • This is the latest in a string of medical policy changes in 2020 that have more than doubled the number of covered lives for average risk NIPT.
  • Natera estimates that there are currently 139 million commercial lives covered in the U.S. for average risk NIPT, representing about 77% of covered lives.
  • Panorama reveals a baby's risk for severe genetic disorders as early as nine weeks into pregnancy.
  • It is the only commercially available test that differentiates between maternal and fetal DNA to assess the risk of aneuploidies.

Natera's Panorama® NIPT Receives Average Risk Coverage for an Additional 24 Million Lives

Retrieved on: 
Thursday, October 8, 2020

"Broadening coverage to this population is an overdue effort to help resolve established and systemic disparities and inequities in women's healthcare."

Key Points: 
  • "Broadening coverage to this population is an overdue effort to help resolve established and systemic disparities and inequities in women's healthcare."
  • "The average risk NIPT market is significantly underpenetrated today.
  • Panorama reveals a baby's risk for severe genetic disorders as early as nine weeks into pregnancy.
  • It is the only commercially available test that differentiates between maternal and fetal DNA to assess the risk of aneuploidies.

Novagen Is Proud to Offer Top DNA Testing Services for The People of Vietnam

Retrieved on: 
Tuesday, May 26, 2020

DNA testing is the process of verifying a blood relationship between two people by comparing specific DNA markers in each person's genome.

Key Points: 
  • DNA testing is the process of verifying a blood relationship between two people by comparing specific DNA markers in each person's genome.
  • Novagen is offering DNA testing services that focus on gene identification services, DNA testing, prenatal DNA testing, genetic testing and NIPT noninvasive prenatal screening.
  • The Novagen testing laboratory is meeting the ISO 9001: 2015 standard and is the first company to apply 27 loci testing technology in DNA testing.
  • Customers of Novagen can access various types of testing and services such as DNA tests for father and son, DNA test for the birth certificate, DNA tests for illegitimate son, prenatal DNA test, non-invasive fetal DNA test , DNA tests for mother and children, DNA testing for Bowel DNA, DNA tests for grandparents and grandchildren, DNA tests for relatives, screening for non-invasive birth defects, sequencing of new generation NGS gene.

Panorama Publication Demonstrates Utility of Measuring Individual Fetal Fractions in Twin Pregnancies

Retrieved on: 
Wednesday, November 27, 2019

When the fetal fractions are discrepant, the signal from the dominant twin obfuscates the signal from the other twin.

Key Points: 
  • When the fetal fractions are discrepant, the signal from the dominant twin obfuscates the signal from the other twin.
  • "The ability to accurately determine zygosity in twin pregnancies, and individual fetal fraction in dizygotic pregnancies, is a major advancement in the management of twin pregnancies," saidPaul Billings, M.D., Ph.D., Natera's Chief Medical Officer.
  • The test also screens twin pregnancies for zygosity, fetal sex of each baby, and identifies risk for more genetic conditions in twin pregnancies than any other NIPT.
  • Validation of a Single-Nucleotide Polymorphism-Based Non-Invasive Prenatal Test in Twin Gestations: Determination of Zygosity, Individual Fetal Sex, and Fetal Aneuploidy.

Non-Invasive Prenatal Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Retrieved on: 
Tuesday, September 3, 2019

Global Non-Invasive Prenatal Testing Market: Overview

Key Points: 
  • Global Non-Invasive Prenatal Testing Market: Overview
    Non-invasive prenatal testing (NIPT) is a novel genetic screening method based on the analysis of cell-free fetal DNA in the maternal plasma.
  • The global non-invasive prenatal testing market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market.
  • Global Non-Invasive Prenatal Testing Market: Key Segments
    Based on test type, the global non-invasive prenatal testing market has been classified into Materni21, Harmony, Panorama, Verifi, NIFTY, and others.
  • In terms of end user, the global non-invasive prenatal testing market has been split into hospitals, diagnostic laboratories, and others.

Publication Demonstrates Unique Ability of Panorama Test to Determine Zygosity in Twin Pregnancies

Retrieved on: 
Monday, August 5, 2019

The study titled "Validation of a Single-Nucleotide Polymorphism-Based Non-Invasive Prenatal Test in Twin Gestations: Determination of Zygosity, Individual Fetal Sex, and Fetal Aneuploidy" can be found here.

Key Points: 
  • The study titled "Validation of a Single-Nucleotide Polymorphism-Based Non-Invasive Prenatal Test in Twin Gestations: Determination of Zygosity, Individual Fetal Sex, and Fetal Aneuploidy" can be found here.
  • The test uses a unique single-nucleotide polymorphism (SNP)-based technology to analyze fetal/placental DNA obtained through a blood draw from the mother.
  • The test also screens twin pregnancies for zygosity, fetal sex of each baby, and identifies risk for more genetic conditions in twin pregnancies than any other NIPT.
  • Validation of a Single-Nucleotide Polymorphism-Based Non-Invasive Prenatal Test in Twin Gestations: Determination of Zygosity, Individual Fetal Sex, and Fetal Aneuploidy.

BillionToOne launches UNITY™ prenatal screen

Retrieved on: 
Thursday, June 27, 2019

Powered by BillionToOne's patent-pending molecular counting technology, UNITY is the only prenatal screen that tests cell-free fetal DNA for cystic fibrosis, spinal muscular atrophy (SMA) and sickle cell disease using just one tube of blood from the mother.

Key Points: 
  • Powered by BillionToOne's patent-pending molecular counting technology, UNITY is the only prenatal screen that tests cell-free fetal DNA for cystic fibrosis, spinal muscular atrophy (SMA) and sickle cell disease using just one tube of blood from the mother.
  • "We're extremely excited about the commercial launch of UNITY, which will make the existing carrier screening process ten times more accurate and efficient," said Oguzhan Atay, CEO and Co-Founder of BillionToOne.
  • UNITY addresses the many challenges of traditional prenatal screening.
  • BillionToOne is also improving accessibility to next-generation prenatal testing by billing UNITY through existing insurance codes for carrier testing, which are reimbursed by most insurance providers, including Medicaid.